AGENUS INC
No enriched coverage for $AGEN in the last 7 days.
No SEC Form 4 filings for $AGEN in the last 30 days.
This article reports on an ARS SEC filing by Agenus Inc. (AGEN) on April 30, 2026, noting a neutral sentiment and low impact. It provides an overview of the company's recent news, SEC filings, and stock data including market cap and industry.
Agenus director Garo H. Armen reported receiving 4,629 shares of common stock as fully vested compensation in lieu of cash salary for the pay period ending April 3, 2026. The shares were valued at $3.33 each, based on the closing price on April 2, 2026. Following this transaction, Mr. Armen directly holds 339,147 shares of Agenus common stock and also has indirect holdings through IRA accounts, a GRAT, and a partnership.
Agenus Inc. reported a Q4 loss of $10.6 million, or 37 cents per share, with adjusted earnings of 56 cents per share. The biotechnology company posted revenue of $32.2 million for the period. For the full year, Agenus reported a net income of $115,000 on revenue of $113.2 million.
